Stay updated on Nivolumab Plus Bevacizumab in GBM Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.

Latest updates to the Nivolumab Plus Bevacizumab in GBM Clinical Trial page
- Check4 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1, while the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previously visible study details with an access restriction notice. This appears to be an access issue rather than a substantive update to the page content.SummaryDifference0.5%

- Check25 days agoChange DetectedA new Revision: v3.7.0 is added, and several older study documents and contributor references (e.g., Informed Consent Form, Study Protocol, Case Comprehensive Cancer Center, David Peereboom) were removed from the page.SummaryDifference22%

- Check46 days agoChange DetectedThe page revision number was updated to v3.6.6, indicating a routine maintenance release rather than substantive content changes.SummaryDifference0.1%

- Check61 days agoChange DetectedAdded Informed Consent Form and Study Protocol/Statistical Analysis Plan as downloadable documents and included related resource links on the study page. These additions provide direct access to official protocol and consent materials.SummaryDifference69%

- Check68 days agoChange DetectedThe page's revision tag was updated to v3.6.5, replacing the previous v3.6.4, indicating a minor update to the study record documentation.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Bevacizumab in GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.